CYP3A5 and POR gene polymorphisms as predictors of infection and graft rejection in post-liver transplant patients treated with tacrolimus - a cohort study.

IF 2.9 3区医学 Q2 GENETICS & HEREDITY

Pharmacogenomics Journal Pub Date : 2025-02-25 DOI:10.1038/s41397-025-00363-4

Graziella D' Agostino Ribeiro Naldi, Ariane Boccoli Minari, Thales D M Pereira, Victor Fossaluza, Nicholas Wagner Eugenio, Marcelo Alves Ferreira, Guilherme H Gregório, Lucas Nacif, Luiz Augusto Carneiro D Albuquerque, Ricardo di Lazzaro Filho, Eduardo Luiz Rachid Cançado, Suzane Kioko Ono

{"title":"CYP3A5 and POR gene polymorphisms as predictors of infection and graft rejection in post-liver transplant patients treated with tacrolimus - a cohort study.","authors":"Graziella D' Agostino Ribeiro Naldi, Ariane Boccoli Minari, Thales D M Pereira, Victor Fossaluza, Nicholas Wagner Eugenio, Marcelo Alves Ferreira, Guilherme H Gregório, Lucas Nacif, Luiz Augusto Carneiro D Albuquerque, Ricardo di Lazzaro Filho, Eduardo Luiz Rachid Cançado, Suzane Kioko Ono","doi":"10.1038/s41397-025-00363-4","DOIUrl":null,"url":null,"abstract":"<p><p>Liver transplantation is the only curative option for patients with advanced stages of liver disease, with tacrolimus used as the immunosuppressive drug of choice. Genetic variability can interfere with drug response, potentially leading to overexposure or underexposure. This study aims to investigate the association of CYP3A4 (rs2740574, rs2242480, rs35599367), CYP3A5 (rs776746, rs10264272), POR (rs1057868) and ABCB1 (rs1128503, rs2229109, rs9282564) gene polymorphisms with infection, acute rejection, and renal failure. The logistic regression model found an influence of CYP3A5 (rs776746) and POR28 (rs1057868) on the development of acute rejection after liver transplantation (p = 0.028). It also found an association between carriers of the variant allele of the POR*28 gene and infection.</p>","PeriodicalId":54624,"journal":{"name":"Pharmacogenomics Journal","volume":"25 2","pages":"4"},"PeriodicalIF":2.9000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41397-025-00363-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Liver transplantation is the only curative option for patients with advanced stages of liver disease, with tacrolimus used as the immunosuppressive drug of choice. Genetic variability can interfere with drug response, potentially leading to overexposure or underexposure. This study aims to investigate the association of CYP3A4 (rs2740574, rs2242480, rs35599367), CYP3A5 (rs776746, rs10264272), POR (rs1057868) and ABCB1 (rs1128503, rs2229109, rs9282564) gene polymorphisms with infection, acute rejection, and renal failure. The logistic regression model found an influence of CYP3A5 (rs776746) and POR28 (rs1057868) on the development of acute rejection after liver transplantation (p = 0.028). It also found an association between carriers of the variant allele of the POR*28 gene and infection.

查看原文本刊更多论文

CYP3A5和POR基因多态性作为他克莫司治疗肝移植后患者感染和移植排斥反应的预测因子——一项队列研究

肝移植是晚期肝病患者唯一的治疗选择，他克莫司被用作免疫抑制药物的选择。遗传变异会干扰药物反应，可能导致过度暴露或暴露不足。本研究旨在探讨CYP3A4 （rs2740574、rs2242480、rs35599367）、CYP3A5 （rs776746、rs10264272）、POR （rs1057868）和ABCB1 （rs1128503、rs2229109、rs9282564）基因多态性与感染、急性排斥反应和肾功能衰竭的关系。logistic回归模型发现CYP3A5 （rs776746）和POR28 （rs1057868）对肝移植术后急性排斥反应的发生有影响（p = 0.028）。它还发现POR*28基因变异等位基因携带者与感染之间存在关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics Journal 医学-药学

CiteScore

7.20

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Pharmacogenomics Journal is a print and electronic journal, which is dedicated to the rapid publication of original research on pharmacogenomics and its clinical applications. Key areas of coverage include: Personalized medicine Effects of genetic variability on drug toxicity and efficacy Identification and functional characterization of polymorphisms relevant to drug action Pharmacodynamic and pharmacokinetic variations and drug efficacy Integration of new developments in the genome project and proteomics into clinical medicine, pharmacology, and therapeutics Clinical applications of genomic science Identification of novel genomic targets for drug development Potential benefits of pharmacogenomics.